Independent imaging review confirmed positive data from primary analysis of REFLECT trial
Eisai announced results from the independent imaging review of the REFLECT study. Results from IIR support the findings of the investigator review per mRECIST, confirming lenvatinib demonstrated statistically significant and clinically meaningful improvements across all secondary efficacy endpoints. January 19, 2018